Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Running, not enrolling · Phase 4

Conditions studied: Lymphoma

In brief

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.

Key facts

Study ID

NCT06049134

Run by

M.D. Anderson Cancer Center

People needed

30

Starts

2023-10-06

Expected to finish

2027-12-01

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.
• Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.
• Patients who are at least 18 years of age.
• Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.

You may not qualify if…

• Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.
• Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.
• Patients who are unable to attend follow-up appointments at designated times at MD Anderson.
• Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.